Finance
Vaccine maker reports second quarter revenue of $1.2 million
Published in Cancer Vaccine Week, September 5th, 2005
Revenue for the quarter and 6 months ended June 30, 2005, was $1.2 million and $3.1 million, respectively, compared to $1.9 million and $4.4 million for the same periods in 2004. Net loss for the quarter and 6 months ended June 30, 2005, was $1.7 million and $4.1 million, respectively, or $0.11 and $0.25 per basic and diluted share, respectively. This compares with a net loss of $0.9 million and $1.4 million for the same periods in 2004, or $0.06 and $0.09 per basic and diluted share, respectively. During the quarter ended June 30, 2005, cash and cash equivalents...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Vaccine Week
Source: Cancer Vaccine Week (2005-09-05)
More Articles from Cancer Vaccine Week
- Cancer Vaccine
Function of tumor-specific T lymphocytes more important than numbers - Cancer Vaccine
Tumor-associated carbohydrate antigens are avenue for cancer prevention - Cancer Vaccine
Vaccine induces autoantibodies to prostate-specific membrane antigen - Leukemia Vaccine
Epitopes of receptor for hyaluronic acid-mediated motility identified - Melanoma Vaccine
Vaccine targets tumor microenvironment for treatment of melanoma - Antiproliferative Activity
Lamprey gonadotropin-releasing hormone III inhibited breast cancer cell growth - More from this issue of Cancer Vaccine Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
